» Articles » PMID: 29572257

SSTR-RADS Version 1.0 As a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2018 Mar 25
PMID 29572257
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Reliable standards and criteria for somatostatin receptor (SSTR) PET are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors. SSTR-RADS could guide the imaging specialist in interpreting SSTR PET scans, facilitate communication with the referring clinician so that appropriate workup for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned peptide receptor radionuclide therapy.

Citing Articles

Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.

Ji X, Chen X, Li K, Zhang Z, Tang L, Li T Chem Biomed Imaging. 2024; 2(3):168-184.

PMID: 39474146 PMC: 11504603. DOI: 10.1021/cbmi.3c00093.


ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging.

Ebner R, Sheikh G, Brendel M, Ricke J, Cyran C Eur Radiol. 2024; .

PMID: 39387873 DOI: 10.1007/s00330-024-11095-7.


Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone Lymphoma.

Werner R, Zhi Y, Dreher N, Samnick S, Kosmala A, Higuchi T Mol Imaging Biol. 2024; 26(5):774-779.

PMID: 39090381 PMC: 11436430. DOI: 10.1007/s11307-024-01940-y.


Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based on Ga-DOTATATE PET/MR.

Gao J, Zhou J, Liu C, Pan Y, Lin X, Zhang Y J Cancer Res Clin Oncol. 2024; 150(5):272.

PMID: 38795250 PMC: 11127844. DOI: 10.1007/s00432-024-05776-5.


Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [F]SiTATE.

Ebner R, Lohse A, Fabritius M, Rubenthaler J, Wangler C, Wangler B Eur Radiol. 2024; 34(11):7222-7232.

PMID: 38769164 PMC: 11519286. DOI: 10.1007/s00330-024-10788-3.